PROCEPT BioRobotics (PRCT) Scheduled to Post Quarterly Earnings on Thursday

PROCEPT BioRobotics (NASDAQ:PRCTGet Rating) is scheduled to be announcing its earnings results after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. PROCEPT BioRobotics has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

PROCEPT BioRobotics (NASDAQ:PRCTGet Rating) last announced its earnings results on Tuesday, March 8th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The firm had revenue of $10.14 million for the quarter. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:PRCT opened at $33.76 on Thursday. The company has a 50-day simple moving average of $31.07 and a 200-day simple moving average of $30.87. PROCEPT BioRobotics has a one year low of $15.38 and a one year high of $47.73. The company has a quick ratio of 19.27, a current ratio of 20.08 and a debt-to-equity ratio of 0.19.

PRCT has been the subject of several analyst reports. SVB Leerink increased their price target on shares of PROCEPT BioRobotics from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, March 9th. Bank of America cut their price target on shares of PROCEPT BioRobotics from $48.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, March 9th. Zacks Investment Research cut shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th. Finally, Guggenheim cut their price target on shares of PROCEPT BioRobotics from $55.00 to $40.00 in a report on Wednesday, March 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of “Buy” and a consensus target price of $36.83.

In other PROCEPT BioRobotics news, major shareholder Global Investors Lp Viking sold 1,249,000 shares of the stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $29.90, for a total value of $37,345,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new position in PROCEPT BioRobotics in the third quarter valued at about $39,000. Citigroup Inc. purchased a new position in PROCEPT BioRobotics in the fourth quarter valued at about $48,000. California State Teachers Retirement System purchased a new position in PROCEPT BioRobotics in the fourth quarter valued at about $99,000. Wells Fargo & Company MN acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $107,000. Finally, Deutsche Bank AG acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $110,000. 62.48% of the stock is owned by institutional investors.

PROCEPT BioRobotics Company Profile (Get Rating)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

See Also

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.